These data support that 92R efficiently blocked the in vivo progression of acute T cell leukemia xenografts and suggest the possibility of using this antibody for therapeutic purposes in human CCR9+ tumors. Here, CCR9 is linked to T-cell acute lymphoblastic leukemia.